Table II.
Dermatologic conditions for which JAK inhibitors have been utilized in patients.
| Disease | Inflammatory mediators |
STAT utilized | JAK utilized | Evidence for oral therapy |
Evidence for topical therapy |
|---|---|---|---|---|---|
|
| |||||
| Alopecia areata | IL-15 | STAT3/ 5 | JAK1/3 | OCT-T30 | CR-R35 |
| OCT-R31 | |||||
| IFN-γ | STAT1 | JAK1, TYK2 | CS-T32,33 | ||
| CR-T29,34,86–89 | |||||
| CR-R28,48,90,91 | |||||
| CR-B85 | |||||
|
| |||||
| Atopic dermatitis | IL-4 | STAT6 | JAK1, JAK3 | CS-T25 | RCT-T26 |
| IL-5 | STAT3/5/6 | JAK2 | |||
| IL-13 | STAT6 | JAK1/2/3, TYK2 | |||
|
| |||||
| Chronic actinic dermatitis | unknown | unknown | CR-T92 | ||
|
| |||||
| Chronic mucocutaneous candidiasis | STAT1 mutation | STAT1 | unclear | CR-R91,93 | |
|
| |||||
| Cutaneous T cell lymphoma | JAK1/3, STAT3/5b mutation | STAT3/5b | JAK1/3 | O5 | |
|
| |||||
| Dermatomyositis | IFN-α/β | STAT1/2/4 | JAK1, TYK2 | CR-T94,95 | |
| CR-R96 | |||||
| IL-6 | STAT1/3 | JAK1/2, TYK2 | |||
| IL-15 | STAT3/5 | JAK1/3 | |||
|
| |||||
| Erythema multiforme | IFN-γ | STAT1 | JAK1, TYK2 | CR-T97 | |
| IL-2 | STAT3/5 | JAK1/3 | |||
|
| |||||
| Graft-versus-host disease (cutaneous) | IL-2 | STAT3/5 | JAK1/3 | CS-R98 | |
| IL-6 | STAT1/3 | JAK1/2, TYK2 | |||
| IL-21 | STAT1/3/5 | JAK1/3 | |||
| IL-22 (TNF-α, IL-17) | STAT1/3/5 | JAK1/2, TYK2 | |||
|
| |||||
| Hypereosinophilic syndrome | IL-5 | STAT3/5/6 | JAK2 | CS-T** | |
| JAK2 mutation (among others) | JAK2 | ||||
|
| |||||
| Lupus erythematosus | IFN-α/β | STAT1/2/4 | JAK1, TYK2 | CR-T99,100 | |
| CR-R101 | |||||
| IFN-γ | STAT1 | JAK1, TYK2 | |||
| IL-6 | STAT1/3 | JAK1/2, TYK2 | |||
|
| |||||
| Mastocytosis / mast cell disease | STAT5 | CR-R102 | |||
| IL-4 | STAT6 | JAK1, JAK3 | |||
| IL-5 | STAT3/5/6 | JAK2 | |||
| IL-13 | STAT6 | JAK1/2/3, TYK2 | |||
|
| |||||
| STING vasculopathy | IFN-α/β (STING mutation) | STAT1/2/4 | JAK1, TYK2 | CR-T100 | |
| CR-R103 | |||||
|
| |||||
| Palmoplantar pustulosis | IL-17 | Unclear | Unclear | CR-T104 | |
|
| |||||
| Polyarteritis nodosa | IL-2 | STAT3/5 | JAK1/3 | CR-T105 | |
| IFN-γ (IL-8) | STAT1 | JAK1, TYK2 | |||
|
| |||||
| Psoriasis | IL-12 | STAT4 | JAK2, TYK2 | RCT-T38,39 | RCT-T41,42 |
| RCT-B16 | |||||
| IL-23 (TNF-α, IL-17) | STAT3/4 | JAK2, TYK2 | * others | CS-R40 | |
|
| |||||
| Vitiligo | IFN-γ | STAT1 | JAK1, TYK2 | CR-T47 | CS-R** |
| CR-R48 | |||||
CR: case reports (<5 patients/study), CS: case series (≥5 patients/study), OCT: open-label clinical trial, RCT: randomized controlled trial. Other: in vitro data on human tumor cells.
*
Multiple earlier studies not included.